Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy, Radiation Therapy, and Vaccine Therapy With Basiliximab in Treating Patients With Glioblastoma Multiforme That Has Been Removed by Surgery

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histopathologic diagnosis of WHO grade III or WHO grade IV high grade glioma~  * Newly diagnosed disease~* Meets the following criteria:~  * The patient must undergo leukapheresis for immunologic monitoring~* Tumor expression of EGFRvIII by immunohistochemistry (IHC) or polymerase chain reaction (PCR)~* No radiographic or cytologic evidence of leptomeningeal or multicentric disease~PATIENT CHARACTERISTICS:~* Karnofsky performance status ≥ 80%~* Curran Group status of I-IV~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No conditions that will potentially confound the study results, including any of the following:~  * Active infection requiring treatment or an unexplained febrile (\> 101.5°F) illness~ * Known immunosuppressive disease or known HIV infection~ * Unstable or severe intercurrent medical conditions such as severe heart or lung disease~* No demonstrated allergy to TMZ~* Able to tolerate TMZ~  * TMZ-induced lymphopenia allowed~* No prior allergic reaction to daclizumab/basiliximab or its components~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No other conventional therapeutic intervention other than steroids, radiation, or temozolomide (TMZ) prior to enrollment~* No prior allogeneic solid organ transplantation~* No prior inguinal lymph node dissection, radiosurgery, brachytherapy, or radiolabeled monoclonal antibodies~* No corticosteroids at a dose above physiologic level except nasal or inhaled steroid at the time of first study vaccination~  * For the purposes of this study, physiologic dose is defined as \< 2 mg of dexamethasone/day~ * Once study vaccinations have been initiated, if patients subsequently require increased steroids, they are permitted to remain on the study~* No prior daclizumab/basiliximab

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: EXPERIMENTAL): Temozolomide, PEP-3-KLH conjugate vaccine, and daclizumab
- Arm II (Type: EXPERIMENTAL): Temozolomide, PEP-3-KLH conjugate vaccine, and normal saline
- Basiliximab (Type: EXPERIMENTAL): Patients will receive basiliximab 20 mg IV with vaccine # 1 only and continue with PEP-3-KLH, temozolomide.

Based on this trial design, predict the completion outcome and termination type (if applicable).